Trial Profile
A phase III, randomized, double-blind study of ceftobiprole versus comparator in the treatment of complicated skin and skin structure infections
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Ceftobiprole medocaril (Primary) ; Ceftazidime; Vancomycin
- Indications Skin and soft tissue infections
- Focus Registrational; Therapeutic Use
- Acronyms STRAUSS-II
- Sponsors Janssen Research & Development; Johnson & Johnson
- 16 May 2018 Results assessing PK and Target Attainment of Ceftobiprole in Asian and Non-Asian Subjects using data from this and one another PK study, published in the Clinical Pharmacology in Drug Development
- 15 Apr 2016 According to a Basilea Pharmaceutica media release, results of pooled post hoc analysis from four phase III studies four double-blind, randomized, phase 3 studies in complicated skin or pulmonary infections were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
- 12 Apr 2016 Results (post-hoc pooled analysis of this and other three studies, n = 3031) assessing clinical cure and mortality presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases.